Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis

被引:54
作者
Lara, Matthew S. [1 ]
Brunson, Ann [2 ,3 ]
Wun, Ted [2 ,3 ]
Tomlinson, Ben [2 ,3 ]
Qi, Lihong [2 ,3 ,4 ]
Cress, Rosemary [2 ,3 ,4 ]
Gandara, David R. [2 ,3 ]
Kelly, Karen [2 ,3 ]
机构
[1] Davis Senior High Sch, Davis, CA USA
[2] Univ Calif Davis, Sch Med, Div Hematol Oncol, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Ctr Comprehens Canc, Sch Med, Sacramento, CA 95817 USA
[4] UC Davis Sch Med, DC Davis Dept Publ Hlth Sci, Davis, CA USA
关键词
Non-small cell lung cancer; Young patients; Cause specific survival; Registry analysis; Epidemiology; Prognosis; EPIDEMIOLOGY; SURVEILLANCE; TRENDS; OLD;
D O I
10.1016/j.lungcan.2014.04.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Non-small cell lung cancer (NSCLC) is uncommonly diagnosed in patients younger than 50 years of age. We analyzed the California Cancer Registry (CCR) to describe epidemiologic characteristics and outcomes in this patient subset and to identify factors prognostic for cause-specific survival (CSS). Methods: Patients diagnosed with NSCLC between 1/1/98 through 12/31/09 and reported to the (CCR) as of October 2011 were included. The primary outcome measure was CSS. Cox regression models were used to evaluate predictors of CSS in young patients with NSCLC, adjusted for potential confounders. Interaction analysis was performed between age groups (<50 vs. >= 50) and specific demographic and tumor covariates. Results: We identified 132,671 lung cancer cases, of which 114,451 (86.3%) had NSCLC. Of these, 6389 (5.6%) were <50 years of age (median, 46 years). The most common histology was adenocarcinoma (3697, 57.9%). Most patients had stage III (1522, 23.8%) or IV (3655, 57.2%) disease. Fewer young patients were diagnosed in recent years (n, % of total NSCLC population of that era): 1998-2001 (2355, 6.0), 2002-2005 (2182, 5.7), and 2006-2009 (1852, 5.0), P<0.001. Multivariate analysis showed that age <50 years was an independent predictor of improved CSS (HR 0.827, P<0.001). Significant predictors of better CSS in patients <50 years included female sex, Asian or Hispanic ethnicity, lower stage, later year of diagnosis, and higher socioeconomic status, among others. Adenocarcinoma histology was not associated with improved CSS in this patient subset (HR 0.987, P=0.78). Interaction analysis revealed that Hispanic race and bronchioloalveolar histology had differential CSS outcomes dependent on age group. Conclusions: This large registry study found that age <50 years is an independent predictor of improved CSS. Variables prognostic for CSS differed somewhat from those in older patients. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:264 / 269
页数:6
相关论文
共 50 条
  • [41] Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Papachristos, A.
    Masinde, S.
    Davis, J. D.
    Gullo, G.
    Rietschel, P.
    Paccaly, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S308 - S309
  • [42] Surgical treatment of non-small cell lung cancer in patients 70 years of age or older
    Ciriaco, P
    Zannini, P
    Carretta, A
    Melloni, G
    Chiesa, G
    Canneto, B
    Puglisi, A
    [J]. INTERNATIONAL SURGERY, 1998, 83 (01) : 4 - 7
  • [43] Staging and surgery for non-small cell lung cancer (NSCLC)
    Alpard, SK
    Zwischenberger, JB
    [J]. SURGICAL ONCOLOGY-OXFORD, 1998, 7 (1-2): : 25 - 43
  • [44] The effect of radiotherapy on the survival of non-small cell lung cancer patients
    Schaafsma, J
    Coy, P
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (02): : 291 - 298
  • [45] Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit
    Rich, A. L.
    Khakwani, A.
    Free, C. M.
    Tata, L. J.
    Stanley, R. A.
    Peake, M. D.
    Hubbard, R. B.
    Baldwin, D. R.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2015, 108 (11) : 891 - 897
  • [46] Lung Cancer Versus Young Cancer: Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?
    Bratova, Monika
    Brat, Kristian
    Hurdalkova, Karolina
    Barinova, Magda
    Drosslerova, Marie
    Kultan, Juraj
    Wanke, Matyas
    Koubkova, Leona
    Krejci, Jana
    Svaton, Martin
    [J]. JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 2022, 11 (05) : 451 - 458
  • [47] EGFR inhibitors in non-small cell lung cancer: More than yesterday (but less than tomorrow)
    Cortot, A. B.
    [J]. REVUE DE PNEUMOLOGIE CLINIQUE, 2010, 66 (06) : 367 - 374
  • [48] An overview of mortality & predictors of small-cell and non-small cell lung cancer among Saudi patients
    Alghamdi, Hatim I.
    Alshehri, Ali F.
    Farhat, Ghada N.
    [J]. JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH, 2018, 7 : S1 - S6
  • [49] Multiple Primary Malignancies in Patients with Non-Small Cell Lung Cancer
    Fujita, Shiro
    Masago, Katsuhiro
    Takeshita, Jumpei
    Togashi, Yosuke
    Hata, Akito
    Kaji, Reiko
    Kokubo, Masaki
    Katakami, Nobuyuki
    [J]. INTERNAL MEDICINE, 2015, 54 (03) : 325 - 331
  • [50] Effect of Pulmonary Functions on Survival in Patients with Operable Non-small Cell Lung Cancer
    Cihanbeylerden, Melek
    Yumrukuz, Merve
    Kurt, Bahar
    Tuccar, Cise
    Safak, Cagla
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (05): : 606 - 612